CJC-1295 No DAC 5mg: Complete Research Guide
Table of Contents
- What Is CJC-1295 No DAC
- Mechanism of Action: How CJC-1295 No DAC Works
- CJC-1295 No DAC vs DAC: Key Differences
- Peptide Reconstitution Guide for CJC-1295 No DAC
- Research Peptide Storage Protocols and Best Practices
- HPLC-Tested Peptides: Ensuring Purity and Quality
- Dosage, Administration, and Research Applications
- Potential Side Effects and Safety Considerations
- Frequently Asked Questions
Last Updated: September 28, 2026
What Is CJC-1295 No DAC
CJC-1295 No DAC is a synthetic 29-amino acid growth hormone-releasing hormone (GHRH) analogue designed for laboratory research applications. Unlike its DAC-modified counterpart, this formulation delivers a shorter half-life and pulsatile release profile, making it an essential tool for researchers studying acute hormone secretion dynamics and receptor kinetics in controlled environments.
The compound functions as a selective ligand binding to GHRH receptors on pituitary somatotrophs. Upon introduction to laboratory models, it initiates intracellular signaling cascades that researchers can track and measure with precision. The pulsatile nature of CJC-1295 No DAC distinguishes it from continuous-release formulations, allowing scientists to observe natural, episodic secretion patterns without the extended half-life complications of bioconjugated variants.
At The Peptides King, we recognize that researchers need compounds they can trust. Our HPLC-tested CJC-1295 No DAC meets rigorous purity standards with verified Certificates of Analysis, ensuring your laboratory work proceeds with confidence. This peptide is particularly valuable for teams investigating the fundamental mechanisms of growth hormone regulation and those developing novel therapeutic approaches grounded in GHRH physiology.
CJC-1295 No DAC is a research-grade GHRH analogue offering pulsatile release kinetics, making it ideal for studying acute hormone dynamics in controlled laboratory settings.
Mechanism of Action: How CJC-1295 No DAC Works
The mechanism of CJC-1295 No DAC centers on its interaction with specific receptor pathways in laboratory models. When introduced to pituitary cell cultures, the peptide acts as a selective agonist, binding directly to GHRH receptors (GHRHR) on somatotroph cell membranes. This binding event triggers a cascade of intracellular signaling mediated by G-protein activation and cyclic adenosine monophosphate (cAMP) elevation.
What makes this formulation distinctive is its pulsatile release profile. Unlike DAC-modified variants that bind covalently to albumin for extended circulation, CJC-1295 No DAC exhibits rapid clearance kinetics. This shorter half-life allows researchers to observe natural, episodic hormone secretion patterns, the same rhythmic pulses that occur in vivo. The compound does not trigger unwanted cortisol or prolactin release, maintaining endocrine baseline integrity during experimentation. This is a key distinction from older, non-selective secretagogues.
The receptor activation process unfolds through well-characterized molecular pathways. Adenylate cyclase activation increases intracellular cAMP, which then modulates downstream protein kinase signaling. This cascade ultimately promotes somatic hormone release without disrupting cellular homeostasis. Researchers tracking these intracellular messenger systems can measure variations in transcription factors, protein synthesis rates, and metabolic response indicators with high precision.
The pulsatile clearance profile of CJC-1295 No DAC makes it ideal for studying natural secretion rhythms compared to continuous-release formulations. This distinction is important for researchers comparing experimental data.
CJC-1295 No DAC vs DAC: Key Differences
Understanding the distinction between CJC-1295 No DAC and its DAC-modified counterpart is critical for selecting the right compound for your research objectives. Both are synthetic GHRH analogues, but their structural modifications create fundamentally different pharmacokinetic profiles.
| Feature | CJC-1295 No DAC | CJC-1295 DAC |
|---|---|---|
| Half-life | Short (minutes to hours) | Extended (days) |
| Release Pattern | Pulsatile | Continuous |
| Receptor Binding | Direct GHRHR interaction | Albumin-protected complex |
| Best For | Acute secretion studies | Long-acting kinetics research |
| Clearance | Rapid renal clearance | Protected from enzymatic degradation |
| Research Application | Natural pulse simulation | Sustained receptor activation |
The DAC modification involves covalent linkage to a Drug Affinity Complex via a maleimide group attached to a lysine residue. This bioconjugation shields the peptide from rapid enzymatic cleavage by dipeptidyl peptidase-4 (DPP-4), extending plasma half-life from minutes to days. The albumin-bound complex circulates continuously, delivering non-pulsatile stimulation to GHRH receptors.
CJC-1295 No DAC, by contrast, remains unmodified at the C-terminus. It undergoes natural enzymatic degradation and renal clearance, resulting in a shorter experimental window but a more physiologically accurate pulsatile secretion profile. This makes it the preferred choice for teams investigating how natural hormone pulses regulate downstream metabolic and endocrine responses.
The choice between these compounds depends entirely on your research question. If you’re studying sustained receptor activation and long-term cellular adaptations, DAC modification extends your observation window. If you’re examining acute secretion dynamics and natural pulsatile patterns, No DAC formulation delivers the kinetics you need.
Peptide Reconstitution Guide for CJC-1295 No DAC
Proper reconstitution is essential for maintaining peptide integrity and ensuring reproducible results across your experiments. CJC-1295 No DAC arrives as a lyophilized powder in a sterile vial, a form optimized for long-term storage and stability. Reconstitution requires careful technique and appropriate diluents to preserve the compound’s molecular structure.
Reconstitution Steps:
-
Prepare your workspace. Work in a clean, temperature-controlled environment. Minimize exposure to direct sunlight and maintain room temperature between 68-72°F. Gather all materials before opening the vial.
-
Select bacteriostatic water as your diluent. Bacteriostatic water (0.9% sodium chloride with 0.9% benzyl alcohol) is the standard choice for peptide reconstitution. The benzyl alcohol acts as a preservative, extending the stability of your reconstituted solution. Avoid standard saline or distilled water, which lack antimicrobial properties.
-
Calculate your volume carefully. Determine the concentration you need based on your experimental protocol. A common approach: for a 5mg vial, add 1mL of bacteriostatic water to create a 5mg/mL concentration. Draw the water into an insulin syringe and measure precisely.
-
Inject the water slowly into the vial. Do not shake or agitate the vial vigorously. Instead, inject the bacteriostatic water slowly down the side of the vial, allowing the lyophilized powder to dissolve gradually. Gentle swirling, not shaking, can help if dissolution is slow.
-
Allow complete dissolution. Wait 5-10 minutes for the powder to fully dissolve. The solution should become clear and colorless. If cloudiness persists, allow additional time; do not force dissolution through aggressive mixing.
-
Store reconstituted solution properly. Refrigerate at 2-8°C (35-46°F) immediately after reconstitution. Properly reconstituted CJC-1295 No DAC remains stable for a limited period under refrigeration. Label the vial with the reconstitution date and concentration.
Common mistake: shaking the vial vigorously during reconstitution. Aggressive agitation can denature the peptide bonds and reduce bioavailability. Gentle swirling preserves molecular integrity and ensures consistent results across your research.
Research Peptide Storage Protocols and Best Practices
Storage conditions directly impact peptide stability, potency, and the reproducibility of your research results. CJC-1295 No DAC in lyophilized form exhibits remarkable stability when stored correctly, but reconstituted solutions require more vigilant management.
Lyophilized Powder Storage:
Store unopened vials at -20°C (-4°F) in a dedicated freezer. Lyophilized peptides are remarkably stable at this temperature and can maintain potency for an extended period. Keep vials in their original sterile packaging to prevent moisture absorption. Avoid repeated freeze-thaw cycles, each cycle introduces ice crystal formation that can damage peptide structure. If you must access a vial multiple times, divide it into smaller aliquots before initial freezing.
Reconstituted Solution Storage:
Once reconstituted with bacteriostatic water, your CJC-1295 No DAC solution requires refrigeration at 2-8°C.
Environmental Factors to Control:
Documentation and Tracking:
HPLC-Tested Peptides: Ensuring Purity and Quality
High-Performance Liquid Chromatography (HPLC) analysis is the gold standard for verifying peptide purity and confirming molecular identity. This analytical technique separates peptide components based on their chemical properties, allowing researchers to quantify the percentage of active compound versus impurities or degradation products.
Dosage, Administration, and Research Applications
CJC-1295 No DAC is administered in laboratory settings through subcutaneous injection into cell cultures or animal models, depending on your experimental design. Dosage protocols vary based on your research objectives and the specific cellular systems you’re investigating.
Typical Research Dosage Ranges:
Administration Technique:
Research Applications:
Potential Side Effects and Safety Considerations
CJC-1295 No DAC is formulated exclusively for laboratory research in controlled environments. It is not approved for human consumption, and all safety considerations below apply only to proper handling in research settings.
Laboratory Safety Handling:
Reconstituted Solution Safety:
Cellular and Tissue Response Considerations:
Storage-Related Hazards:
Never attempt to use CJC-1295 No DAC outside of controlled laboratory environments. This research compound is not formulated, approved, or intended for human consumption or therapeutic use. Strict adherence to laboratory protocols and proper storage ensures safe handling and reliable experimental results.
Frequently Asked Questions
What is the primary purpose of CJC-1295 No DAC in laboratory research?
CJC-1295 No DAC is a synthetic GHRH analog studied in laboratory settings to evaluate growth hormone secretagogue receptor signaling and pulsatile release patterns. Unlike the DAC version, the No DAC formulation exhibits a shorter half-life, making it valuable for researchers studying rapid receptor kinetics and acute endocrine responses. Its dual-pathway mechanism targeting both GHRH and ghrelin receptors allows scientists to observe complex neuroendocrine interactions in controlled in vitro models.
How does the half-life of CJC-1295 No DAC differ from the DAC version?
CJC-1295 No DAC has a significantly shorter half-life, typically measured in minutes to hours, because it lacks the Drug Affinity Complex that would bind it to albumin. The DAC version, by contrast, exhibits an extended half-life measured in days due to its covalent attachment to endogenous albumin molecules, which protects it from enzymatic degradation by dipeptidyl peptidase-4 (DPP-4). This fundamental difference makes No DAC ideal for studying pulsatile signaling, while DAC formulations are used for continuous receptor simulation studies.
What are the standard storage requirements for 5mg CJC-1295 No DAC vials?
CJC-1295 No DAC 5mg vials should be stored at -20°C in a cool, dry environment to maintain peptide stability and prevent degradation of the lyophilized powder. Keep vials in their original sterile containers away from direct light and moisture. Once reconstituted with bacteriostatic water, the solution typically remains stable for a limited period when refrigerated at 2-8°C, though researchers should verify stability timelines based on their specific laboratory protocols and quality assurance standards.
How do researchers verify the purity of CJC-1295 No DAC?
Purity verification relies on high-performance liquid chromatography (HPLC) analysis, the gold standard for peptide quality assessment. HPLC separates the peptide compound from potential impurities and contaminants, providing a precise purity percentage. Reputable suppliers like The Peptides King provide verified Certificates of Analysis (COAs) documenting HPLC results alongside mass spectrometry data. These documentation standards ensure researchers receive research-grade materials suitable for rigorous scientific work and reproducible results across studies.
What is the significance of HPLC testing for research peptides?
HPLC testing is critical because it confirms peptide identity, purity, and absence of contaminants that could compromise research validity. For CJC-1295 No DAC and similar compounds, HPLC analysis detects degradation products, synthetic byproducts, and impurities that might interfere with receptor binding studies or cellular assays. Verified HPLC-tested peptides from trusted suppliers ensure consistency across experimental batches, allowing researchers to isolate variables and achieve reproducible results, essential for peer-reviewed publication and regulatory compliance in laboratory research.